India’s largest drugmaker will commence Phase II trials on 210 patients across 12 centers in India and the results are expected by October, according to an
This is the first phytopharmaceutical -- or plant-based -- drug permitted for a clinical trials by the Indian drug regulator to fight the deadly pathogen that’s sickened 6.6 million people globally and has no approved cure or vaccine yet. Sun Pharma’s experimental drug is among the few candidates among the hundreds being tested worldwide to emerge from India, a country better known for making cheap generic versions of drugs developed elsewhere.
Sun Pharma’s shares rose as much as 3.3% on Friday in Mumbai, reaching their
Positive early results in in-vitro and small animal studies gave Sun Pharma the confidence to evaluate this potential treatment option,
Effectiveness was seen in in-vitro studies conducted in collaboration with Italy’s International Center for Genetic Engineering and Biotechnology, said the statement.
To contact the reporter on this story:
To contact the editors responsible for this story:
© 2020 Bloomberg L.P. All rights reserved. Used with permission.